Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
National Institute for Clinical Excellence
Record ID 32000001775
English
Authors' objectives:
To provide guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes.
Authors' recommendations:
Guidance 1.1 This guidance applies to patients with unstable angina or non-Q-wave myocardial infarction and those patients undergoing acute or elective percutaneous coronary intervention (PCI).
1.2 For high-risk patients with unstable angina or non-Q-wave myocardial infarction the intravenous use of the glyc o p rotein IIb /IIIa (GP IIb/IIIa) inhibitors (consistent with current UK licensing), in addition to aspirin and low (adjusted) dose unfractionated heparin, is recommended.
1.3 In unstable angina, raised blood levels of troponin should be used to identify those at high risk.
1.4 For patients undergoing acute or elective percutaneous coronary intervention (PCI), the intravenous use of GP IIb/IIIa inhibitors (consistent with current UK licensing) is recommended.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=10250
Year Published:
2000
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Glycoproteins
- Myocardial Ischemia
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.